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Abstract Purpose:Tibolone is a selective tissue estrogenic activity regulator, approved for the treatment
of vasomotor symptoms in postmenopausal women.We have done an exploratory, double-blind,
randomized, placebo-controlled pilot trial to investigate the tissue-specific effects of 2.5 mg
tibolone on breast cancer in postmenopausal women, in particular on tissue proliferation
(STEM, Study ofTibolone Effects on Mamma carcinoma tissue).
Experimental Design: Postmenopausal women with initially stage I/II, estrogen receptor ^
positive (ER+) primary breast cancer, were randomly assigned to 14 days of placebo or
2.5 mg/d tibolone. Core biopsies of the primary tumor were obtained before and after treatment.
Ki-67 and apoptosis indexwere analyzed inbaseline and correspondingposttreatment specimen.
Results: Of 102 enrolled patients, 95 had evaluable data. Baseline characteristics were compa-
rable between both treatment groups. Breast cancer cases aremainly invasive (99%), stage I or II
(42% and 50% respectively), and ER+ (99%). Median intratumoral Ki-67 expression at baseline
was 13.0% in the tibolone group and 17.8% in the placebo group, and decreased to 12.0% after
14 days of tibolonewhile increasing to19.0% in the placebo group.This change frombaselinewas
not significantly different between tibolone and placebo (Wilcoxon test; P = 0.17). A significant
difference was observed between the treatment groups when the median change from baseline
apoptosis index was compared between the treatment groups (tibolone, 0.0%; placebo, +0.3%;
Wilcoxon test; P = 0.031).The incidence of adverse effects was comparable.
Conclusions: In ER+breast tumors, 2.5mg/d tibolone given for14 dayshas no significant effect
on tumor cell proliferation.
Vasomotor symptoms are a major side effect of adjuvant breast
cancer treatment and it has been estimated that up to 96% of
women who undergo chemotherapy or endocrine therapy
suffer from hot flashes or night sweats (1). Although these
symptoms are thought to result from systemic estrogen and
progestin deprivation and can effectively be treated by
hormone replacement therapy in patients who are not taking
tamoxifen, such a therapeutic strategy is contraindicated,
mainly because of a fear of the proliferative and tumor-
promoting effects attributed to sex steroids (2). Unfortunately,
the efficacy and safety of phytoestrogens as alternatives in the
treatment of vasomotor symptoms is unproven and nonhor-
monal therapies with serotonin reuptake inhibitors and gaba-
pentin are, at best, approximately half as effective as estrogen
(3, 4). In addition, nonhormonal therapies have no effect on
other postmenopausal symptoms such as bone loss or urogenital
atrophy (5).
Tibolone (Livial) is a selective tissue estrogenic activity
regulator, approved for the treatment of climacteric symptoms
in postmenopausal women. Following oral administration, it is
converted into three primary metabolites, of which the 3a-
hydroxymetabolite and the 3h-hydroxymetabolite only bind to
the estrogen receptor a, whereas the parent compound tibolone
and its D4-isomer bind to the progesterone and androgen
receptors. The metabolism is tissue specific and results in a
highly favorable profile of effects: Although tibolone exerts
estrogenic effects on bone, brain, and the urogenital system
through its hydroxymetabolites, it does not seem to stimulate
endometrium or to increase breast tissue proliferation (6). It
has been proposed that the lack of an estrogenic effect on breast
tissue may result from the inhibition of sulfatase and the
stimulation of sulfotransferase in this tissue (7, 8). Indeed,
clinical studies have shown that compared with women who
Cancer Therapy: Clinical
Authors’Affiliations: 1Division of Special Gynecology, Medical University of
Vienna, Vienna, Austria; 2Global Clinical Development, NV Organon, Oss, the
Netherlands; 3Department of Academic Biochemistry, Royal Marsden Hospital,
London, United Kingdom; 4Department of Obstetrics and Gynecology, University
of Lie' ge, Liege, Belgium; 5Department of Obstetrics and Gynecology II, Comenius
University School of Medicine, Bratislava, Slovak Republic; 6Department of
Gynecology, University of Ghent, Ghent, Belgium; 7Cancer Research Center,
Moscow, Russia; and 8St. Petersburg City Clinical Oncology Dispensary and
9St. Petersburg Research Institute of Oncology, St. Petersburg, Russia
Received11/13/06; revised 2/24/07; accepted 5/8/07.
The costs of publication of this article were defrayed in part by the payment of page
charges.This article must therefore be hereby marked advertisement in accordance
with18 U.S.C. Section1734 solely to indicate this fact.
Potential conflicts of interest: J.V.M. Planellas Gomez and C.C.M. Hageluken
are employed by NVOrganon.
Requests for reprints:Christian F. Singer, Division of Special Gynecology,Vienna
Medical University,Vienna, Austria. Phone: 43-1-40400-2801; Fax: 43-1-406-
6749; E-mail: Christian.singer@meduniwien.ac.at.
F2007 American Association for Cancer Research.
doi:10.1158/1078-0432.CCR-06-2700
www.aacrjournals.org Clin Cancer Res 2007;13(14) July15, 20074185
use continuous combined hormone treatment, tibolone users
experience considerably less breast tenderness and do not
develop an increase in mammographic density (9). Breast safety
studies in the 7,12-dimethylbenz(a)anthracene model have
shown that tibolone is highly effective in reducing tumor
growth in mice (10). In addition, tibolone inhibits the sulfatase
enzyme and promotes apoptosis in normal as well as breast
cancer cells, thus suggesting a local antiestrogenic effect (11).
The observation that tibolone is also able to decrease the
proliferation rate of normal and malignant breast epithelial
cells in vitro warrants particular attention (12, 13, 14). Dowsett
et al. (15) have recently shown that the nuclear antigen Ki-67,
which is expressed in proliferating cells, is an appropriate end
point in neoadjuvant models of response to long-term
endocrine therapies.
We have therefore studied tissue-specific effects of 14 days
of 2.5 mg tibolone on breast cancer in postmenopausal
women, in particular on the proliferation marker Ki-67 and
on apoptosis, to support the hypothesis that tibolone has no
adverse effects on malignant breast tissue.
Patients andMethods
Study design. The STEM (Study of Tibolone Effects on Mamma
carcinoma tissue) study is a randomized, placebo-controlled, double-
blind, multicenter, exploratory trial, in which postmenopausal women
with initially stage I or II, estrogen receptor–positive (ER+) primary
breast cancer were randomized 1:1 to receive a preoperative daily oral
dose of 2.5 mg tibolone, or placebo for 14 days until surgery. Eligible
patients had previously untreated, core-biopsy proven, invasive breast
cancer without evidence of metastatic spread and any endocrine or
enzyme modulator therapy was stopped at least 3 months before
randomization.
Objectives. The aim of the trial was to confirm the safety of tibolone
on breast tissue in women with early breast cancer as measured by the
breast safety surrogate variables Ki-67 and apoptosis index. The primary
trial objective was to compare changes in the expression of the
proliferation marker Ki-67 label index in malignant breast tissue after
treatment with tibolone or placebo for 14 days. Secondary objectives
were the evaluation of treatment effects on tumor apoptosis index, on
apoptosis-related proteins Bcl-2 and Bax, hormone receptors, hormone-
sensitive proteins, tumor vascularization, and angiogenesis. Moreover,
endogenous estrogen levels and tibolone and tibolone metabolites in
serum and breast tissue were measured. In addition, monitoring of
(serious) adverse events, clinically significant abnormal laboratory
values and summary statistics for vital signs was done to evaluate the
overall safety of tibolone in women with early breast cancer. Although
we here report the effect of tibolone, compared with placebo, on tumor
proliferation and apoptosis and on overall safety in women with
early breast cancer, other secondary end points will be presented
elsewhere. The study was done in accordance with the ethical principles
of the Declaration of Helsinki and was approved by the local
institutional review board at all study sites. Only women who had
given written voluntary informed consent were included into the trial.
Block randomization was done per center to ensure that treatments
were equally distributed in each of the participating centers. In total,
102 women were randomized in 14 sites in five countries between
March 2003 and April 2005. Patient and tumor characteristics of
women randomized into the tibolone and the placebo arm are depicted
in Table 1.
Tumor assessments. Tumor samples were obtained by core biopsies
at screening and after 14 days of treatment with study medication from
the excised tumor at surgery. A minimum of three core biopsy samples
was required per biopsy site to ensure a representative evaluation of
proliferation and apoptosis. For each patient, Ki-67 and apoptosis
index were analyzed, by immunohistochemistry, in both baseline and
the corresponding posttreatment excision samples. Measurement of cell
proliferation was done by using the MIB1 mouse monoclonal antibody
to Ki-67 and counting the number of positive cells in a random sample
of 1,000 cells. Apoptotic cells were identified by immunostaining using
the terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick
end-labeling method. The apoptotic index was expressed as a
percentage of the total number of cells displaying apoptotic bodies in
a random sample of 1,000 cells. The relative Bcl-2 and Bax gene
expression was determined by semiquantitative reverse transcription-
PCR after extraction from snap-frozen tissue samples. Relative values
were expressed as the ratio of specific transcripts/28S transcripts. All
reverse transcription-PCR experiments were carried out at least thrice in
duplicate on two different cDNA preparations.
Statistical measurements. For all breast tissue safety variables,
descriptive summary statistics, number (n), median, mean, and SE
were calculated for the intent-to-treat group. Subjects within this intent-
to-treat group have received trial treatment (placebo or tibolone) and
also have had a post–baseline assessment on Ki-67. The safety of
tibolone versus placebo on the breast was explored by comparing the
Table 1. Baseline patient characteristics (intent-to-treat group)
Variable Tibolone (n = 46) Placebo (n = 49)
Median Mean (SE) Median Mean (SE)
Age (y) 66 64.8 (1.1) 65 65.1 (1.1)
Weight (kg) 71 70.6 (1.3) 70 70.2 (1.3)
Height (cm) 161 160.8 (1.2) 160 160.6 (1.2)
BMI (kg/m2) 28 27.4 (0.5) 28 27.2 (0.5)
Age at last menses (y) 50 48.4 (0.8) 49 48.1 (0.8)
Time since menopause (y) 17.1 16.4 (1.4) 14.6 17.0 (1.4)
Frequency distribution Tibolone (n = 46) Placebo (n = 49)
ER at screening (%)
Positive 46 (100%) 49 (100%)
Tumor stage, clinical (%)
I 18 (39%) 21 (43%)
II 24 (52%) 24 (49%)
III 2 (4%) 3 (6%)
IV 0 (0%) 1 (2%)
Unknown 2 (4%) 0 (0%)
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postbaseline change from baseline measurements of Ki-67, apoptosis
index, and the relative gene expression levels of Bcl-2 and Bax by
Wilcoxon tests. All analyses were done using SAS Version 8.2 or higher
under Windows NT.
Results
Patients. The study cohort consisted of elderly (mean age
f65 years), postmenopausal women with a mean body mass
index of slightly over 27 years, who suffered from breast cancer.
There were no significant differences between the groups at
baseline. At screening, tumor status in f90% of patients was
ER+ and also tumor staging was comparable between groups.
Although at the time of randomization, all patients presented
with stage I and II disease, the complete postoperative histologic
evaluation of tumor size and lymph node involvement resulted
in an upstaging in six patients. The main patient characteristics
are presented in Table 1 for the intent-to-treat group.
Intratumoral Ki-67 protein expression in pretherapeutic and
posttherapeutic breast cancer biopsies. Table 2 shows the
intratumor levels of Ki-67 at baseline and after 14 days of trial
treatment. The median baseline Ki-67 levels were 13.0% in the
tibolone arm and 17.8% in the placebo arm, whereas median
posttreatment levels ranged from 12.0% in the tibolone arm to
19.0% in the placebo arm. The difference between the
treatment groups in changes from baseline in intratumoral
Ki-67 expression of -2.4% in the tibolone group and of +0.2%
in the placebo group was nonsignificant (Wilcoxon test,
P = 0.17). The individual changes from baseline in Ki-67 are
presented in Fig. 1.
Intratumoral apoptosis index and Bcl-2 and Bax gene
expression in response to tibolone. The intratumoral apoptosis
index measured at baseline and after 14 days of treatment with
2.5 mg tibolone or placebo are shown in Table 3 for the intent-
to-treat group. The median pretreatment apoptosis index in
both the tibolone arm and the placebo arm was 1.4%, whereas
the mean posttreatment apoptosis index was 1.6% in the
tibolone arm, and 1.7% in the placebo arm. The resulting net
changes in the median intratumoral apoptosis index were 0.0%
in the tibolone group and 0.3% in the placebo group
(Wilcoxon test on treatment differences P = 0.03).
Summary statistics of apoptosis-related proteins Bcl-2 and
Bax mRNA expression at baseline and surgery showed similar
results (Table 3). Median values of the antiapoptotic marker
Bcl-2 and the proapoptotic marker Bax were not changed
significantly by either tibolone or placebo (Wilcoxon test: Bax,
P = 0.739; Bcl-2, P = 0.642).
Overall patient safety. Treatment with 2.5 mg tibolone for
14 days was safe and well tolerated. No significant differences
between tibolone and placebo were observed with respect to
the incidence and type of adverse events (Table 4). The most
frequent adverse events during tibolone treatment were
postprocedural pain (13.7%), asthenia (10%), and pyrexia
(8%). Two serious adverse events occurred, an ischemic stroke
in the tibolone group and a postoperative wound infection in
the placebo group. Tibolone treatment was only discontinued
once (2%), in response to one serious adverse event (ischemic
stroke). As expected, treatment with 2.5 mg tibolone for
14 days did not significantly alter blood pressure or heart rate
(data not shown).
Discussion
It is estimated that f70% of women who suffer from breast
cancer are postmenopausal. The remaining 30% will often
become postmenopausal as a result of their cancer treatment.
Climacteric symptoms are thus an increasingly relevant side
effect of antineoplastic strategies, and associated symptoms
such as hot flashes and night sweats can considerably affect
quality of life (16). Although hormone treatment effectively
ameliorates vasomotor symptoms, its use is contraindicated in
women with a history of breast cancer. These recommendations
are mostly based on the proliferative effect of estrogens on
tumor cells in vitro, but also on epidemiologic evidence for an
increase in breast cancer incidence that is especially strong in
estrogen/progestin–containing hormone replacement therapy
formulations (17). At least three large trials have attempted to
evaluate the safety of hormone replacement therapies in
women with a history of breast cancer but none of them has
been able to recruit sufficient patients, largely because of a fear
of increased recurrence (18). A recently conducted meta-
analysis of several smaller trials did not find an increase in
breast cancer recurrence or in cancer-associated mortality with
estrogen or estrogen progestin treatment, although one
prospectively randomized trial was terminated early because
of the finding that the treatment increased the risk of recurrence
(19, 20). Thus far, no effective treatment for the alleviation of
menopausal symptoms has been approved for women with
breast cancer.
Tibolone is a synthetic steroid that is distinct from currently
available hormone treatment because of its mode of action and
by its favorable clinical profile (21). In vitro , tibolone and its
D4-isomer have antiproliferative effects on normal breast cells
and increase apoptosis in both normal and malignant breast
Table 2. Changes in intratumoral Ki-67 protein expression in response to 14 d of treatment (intent-to-
treat group)
Baseline Surgery Change from baseline P*
Tibolone Placebo Tibolone Placebo Tibolone Placebo
Ki-67 (%) 0.170
n 46 49 46 49 46 49
Median 13.0 17.8 12.0 19.0 -2.4 0.2
Mean (SE) 18.2 (2.2) 21.6 (2.8) 16.3 (2.3) 22.0 (2.4) -1.9 (2.1) 0.4 (1.2)
NOTE: n = number of patients.
*Wilcoxon test on treatment differences for change from baseline.
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epithelium, presumably through decreased expression of the
antiapoptotic proteins Bcl-2 and Bax (22). In addition, tibolone
and its 3h-hydroxy metabolite and also the D4-isomer exert
anti-invasive effects on breast cancer cell lines in vitro .
Two recent smaller trials have suggested that tibolone may
indeed be safe in women with a history of breast cancer: An
observational study has recently found no increase in systemic
recurrences or contralateral breast cancer in 156 breast cancer
survivors who have received tibolone for 18 to 96 months
when compared with placebo after completion of 5 years of
tamoxifen (23). In addition, Kroiss et al. (24) have shown the
efficacy of tibolone in the reduction of hot flushes in
Table 3. Changes in intratumoral apoptosis index, and relative Bcl-2 and Bax gene expression in response to
14 d of treatment (intent-to-treat group)
Baseline Surgery Change from baseline P*
Tibolone Placebo Tibolone Placebo Tibolone Placebo
Apoptosis index (%) 0.031
n 41 40 44 48 39 39
Median 1.4 1.4 1.6 1.7 0 0.3
Mean (SE) 1.5 (0.12) 1.5 (0.11) 1.6 (0.12) 1.7 (0.10) 0 (0.08) 0.3 (0.08)
Bcl-2 (%) 0.739
n 28 21 28 21 28 21
Median 0.8 0.9 1 1 0.1 0.1
Mean (SE) 0.8 (0.06) 0.9 (0.07) 1 (0.09) 1.1 (0.11) 0.2 (0.09) 0.3 (0.13)
Bax (%) 0.642
n 28 21 28 21 28 21
Median 0.6 0.6 0.7 0.7 0.1 0
Mean (SE) 0.5 (0.04) 0.6 (0.04) 0.7 (0.08) 0.9 (0.15) 0.2 (0.08) 0.3 (0.15)
NOTE: The relative Bcl-2 and Bax gene expression is depicted as the ratios of the specific transcript/28S transcript.
*Wilcoxon test on treatment differences for change from baseline.
Fig. 1. Individual changes from baseline in Ki67 protein levels after 2 wk in the tibolone (left) and placebo (right) groups.
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tamoxifen-treated breast cancer patients. Although only 70
patients were enrolled into the trial, none of the women in the
tibolone arm experienced a recurrence during the 12 months of
treatment and no endometrial stimulation was observed in the
tibolone/tamoxifen arm.
The favorable therapeutic profile has led to the design of the
‘‘Livial Intervention following Breast Cancer; Efficacy, Recur-
rence, and Tolerability Endpoints’’ (LIBERATE) study, an
international multicenter trial that has recruited >3,000 patients
and that is expected to report a first analysis by end of 2007.
The aim of the study is to show noninferiority of tibolone
compared with placebo in respect to breast cancer recurrence
and to show that tibolone is safe and effective in women with
breast cancer and vasomotor symptoms. Recently, however, the
use of tibolone has been associated with an increased relative
risk for the development of breast cancer in a large cross-
sectional cohort trial (25). Although it should be noted that in
this study only 88 of the 7,140 women who developed breast
cancer during the observational period had exclusively received
tibolone as hormone treatment, this unexpected observation
has prompted further investigation of an explanation for this
finding. It can, at least partly, be explained by the widespread
practice of ‘‘preferential prescribing’’: Women with a history of
breast cancer or chronic breast disease and women from high
breast cancer risk families are more likely to receive tibolone for
alleviation of their climacteric symptoms than estrogen-
progestin combinations because of the perceived ‘‘breast safety’’
of tibolone by many physicians (26, 27).
We have studied the effects of tibolone on malignant breast
tissue in an in vivo model that has been suggested to parallel
long-term endocrine effects: Dowsett et al. (15) have recently
shown that changes in intratumoral Ki67 protein expression
under neoadjuvant endocrine therapy can correspond to the
disease-free survival in the large adjuvant ATAC Trial. Ki67 is
therefore now increasingly used as an end point in neoadjuvant
studies, and our observation of essentially unchanged Ki67
levels in biopsies from the placebo group that were taken
2 weeks apart underscore the appropriateness of this approach
(28). Our results are also somewhat support observations by
Valdivia et al. (29), who even showed that a 12-month
treatment with tibolone leads to a reduction in Ki67 expression
and to a stimulation of apoptosis, albeit in normal breast tissue
of postmenopausal women. Although, in contrast to their
findings, we did not observe an increase in intratumoral
apoptosis by tibolone, we did find a nominal but insignificant
reduction in Ki67. The attenuated effect of tibolone that is seen
in tumor tissue can at least in part be explained by the fact that
whereas in normal breast tissue the effect of tibolone is
measured in more or less homogenous tissues, in malignant
breast tumors the situation is considerably more complex: Core
biopsies can contain considerably different fractions of tumor
cells and tumor stroma, and the biological activity of tumor
cells also varies from patient to patient, which could have
somewhat weakened the effect of the compound. We have,
however, no explanation for the fact that 14 days of placebo
result in a significant increase of apoptosis.
Taken together, the STEM trial has shown that tibolone, a
commonly prescribed hormone replacement therapy, given for
14 days in postmenopausal women with ER+ breast cancer, has
no adverse effect on the expression of the proliferation marker
Ki-67 and on surrogate variables of apoptosis in malignant
epithelium. To our knowledge, this is the first clinical trial that
has investigated the proliferative and apoptotic effects of a
hormone replacement therapy in breast cancer patients in the
preoperative setting. If the still ongoing LIBERATE trial indeed
shows that tibolone given for 5 years has no adverse effects on
tumor recurrence, our results would complement previous
findings by the IMPACT trial and thus provide further evidence
for the usefulness of short-term neoadjuvant in vivo assays.
Preoperative in vivo studies such as the one presented here
might thus potentially allow us to predict the long-term
outcomes of novel endocrine therapies in a small, safe, and
short in vivo setting, and eventually help to avoid unnecessarily
lengthy and considerably more expensive adjuvant trials in the
future.
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Table 4. Adverse events (all subjects treated
group)
Tibolone
(n = 51)
Placebo
(n = 51)
Adverse events, total 17 (33%) 14 (28%)
Postprocedural pain 7 (14%) 4 (8%)
Asthenia 5 (10%) 5 (10%)
Pyrexia 4 (8%) 2 (4%)
Nausea 3 (6%) 1 (2%)
Dizziness 3 (6%) 0 (0%)
Headache 3 (6%) 0 (0%)
Serious adverse events, total 1 (2%) 1 (2%)
Ischemic stroke 1 (2%) 0 (0%)
Postoperative wound infection 0 (0%) 1 (2%)
Serious adverse event leading
to discontinuation
1 (2%) 0 (0%)
Death 0 (0%) 0 (0%)
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